CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany

Rhea-AI Summary

CytoDyn announces its participation in the upcoming ESMO Breast Cancer meeting in Munich, Germany, scheduled for May 14-17, 2025. The company will present promising survival data for its drug leronlimab in treating metastatic triple-negative breast cancer (mTNBC).

Key highlights:

• CEO Dr. Jacob Lalezari and Lead Consultant Dr. Richard Pestell will lead the presentation
• Poster presentation scheduled for May 15, 2025
• Notable survival rates observed at 12, 24, and 36 months
• Four patients show no evidence of disease after 48 months
• One additional patient maintains stable disease

The company reports these outcomes compare favorably to current approved therapies and suggests a potential paradigm shift in solid tumor oncology treatment. CytoDyn has initiated a follow-up protocol to monitor surviving patients.

Positive

• Promising survival observations in metastatic triple-negative breast cancer (mTNBC) patients treated with leronlimab
• Long-term survival data shows patients living beyond 48 months after leronlimab treatment
• 4 patients show no evidence of disease and 1 patient has stable disease after treatment
• Potential breakthrough in solid tumor oncology treatment based on mechanism of action

Negative

• Company still trades on OTCQB market, indicating lower tier exchange listing

Dr. Jacob Lalezari, CEO, and Dr. Richard Pestell, Lead Consultant in Preclinical and Clinical Oncology, to
lead CytoDyn group in attendance

VANCOUVER, Washington, April 29, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, is pleased to announce that the Company will be presenting a poster at the upcoming European Society for Medical Oncology’s (“ESMO”) Breast Cancer meeting, following its promising survival observations among patients with metastatic triple-negative breast cancer (“mTNBC”) treated with leronlimab. The conference will take place on May 14-17, 2025, in Munich, Germany, and CytoDyn’s presentation is scheduled for May 15, 2025.

As announced in February 2025, a review of patients treated with leronlimab during CytoDyn’s prior clinical trials in oncology revealed observed survival rates at 12, 24, and 36 months that compare favorably to expected outcomes with currently approved therapies. The Company has also now confirmed survival outcomes in a group of patients with mTNBC and four prior lines of treatment who are alive more than 48 months after receiving leronlimab. This includes four patients who currently identify as having no evidence of ongoing disease and a fifth patient who is alive with stable disease. CytoDyn has already initiated a follow-up protocol to continue to monitor these surviving patients into the future.

“We look forward to sharing details on the progress we have made advancing our clinical development pipeline for leronlimab in oncology,” said Dr. Lalezari. “We are also excited to share information about the apparent mechanism of action in long-term surviving patients that we see as a potentially paradigm-shifting development in solid tumor oncology.”

Dr. Lalezari will be joined at the conference by Dr. Richard Pestell, MD, PhD, AO, Lead Consultant in Preclinical and Clinical Oncology, who will present during the poster display session in Hall B0 on Thursday, May 15 from 12:00-12:45PM CEST. Several other CytoDyn key opinion leaders will also be attending the conference.

About CytoDyn

CytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells that is believed to play a role in numerous disease processes. CytoDyn has studied leronlimab in multiple therapeutic areas, including oncology, infectious disease, and autoimmune conditions.

Note Regarding Forward-Looking Statements

This news release contains forward-looking statements relating to, among other things, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2024, including the section captioned “Forward-Looking Statements” and Item 1A Risk Factors, and our Quarterly Report on Form 10-Q for the fiscal quarter ended February 28, 2025. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Media Contacts

CytoDyn
Riyaz Lalani
Gagnier Communications
CytoDyn@gagnierfc.com

FAQ

What are the survival rates for CYDY's leronlimab in metastatic triple-negative breast cancer patients?

CytoDyn reported favorable survival rates at 12, 24, and 36 months compared to current therapies. Notably, five mTNBC patients who received leronlimab after four prior treatments have survived beyond 48 months, with four showing no evidence of disease and one having stable disease.

When will CYDY present at ESMO Breast Cancer Meeting 2025 in Munich?

CytoDyn will present their poster on May 15, 2025, from 12:00-12:45PM CEST in Hall B0 at the ESMO Breast Cancer Meeting in Munich, Germany. The conference runs from May 14-17, 2025.

What breakthrough has CYDY achieved with leronlimab in cancer treatment?

CytoDyn has discovered what they describe as a potentially paradigm-shifting development in solid tumor oncology, related to leronlimab's mechanism of action in long-term surviving patients with metastatic triple-negative breast cancer.

How many mTNBC patients treated with CYDY's leronlimab are disease-free?

Among the long-term survivors treated with leronlimab who had four prior lines of treatment, four patients currently show no evidence of ongoing disease, while one additional patient is alive with stable disease.

What is the next step for CYDY's leronlimab cancer research?

CytoDyn has initiated a follow-up protocol to continue monitoring the surviving mTNBC patients who have responded positively to leronlimab treatment, while also presenting their findings at the ESMO Breast Cancer Meeting in May 2025.